Perkins Capital Management Inc. Purchases 24,250 Shares of Codexis, Inc. (NASDAQ:CDXS)

Perkins Capital Management Inc. boosted its position in shares of Codexis, Inc. (NASDAQ:CDXS) by 14.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 188,350 shares of the biotechnology company’s stock after buying an additional 24,250 shares during the period. Perkins Capital Management Inc.’s holdings in Codexis were worth $898,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Barclays PLC boosted its position in shares of Codexis by 51.1% during the 3rd quarter. Barclays PLC now owns 207,628 shares of the biotechnology company’s stock valued at $640,000 after acquiring an additional 70,255 shares during the last quarter. Geode Capital Management LLC lifted its position in Codexis by 0.7% during the third quarter. Geode Capital Management LLC now owns 1,644,039 shares of the biotechnology company’s stock valued at $5,065,000 after purchasing an additional 11,082 shares during the last quarter. State Street Corp grew its stake in shares of Codexis by 2.7% in the 3rd quarter. State Street Corp now owns 1,551,411 shares of the biotechnology company’s stock worth $4,778,000 after buying an additional 41,480 shares in the last quarter. Tallon Kerry Patrick bought a new stake in shares of Codexis in the 4th quarter worth about $2,018,000. Finally, Inspire Investing LLC purchased a new stake in shares of Codexis during the 4th quarter valued at about $405,000. Hedge funds and other institutional investors own 78.54% of the company’s stock.

Codexis Stock Performance

CDXS opened at $2.55 on Monday. The stock has a 50-day moving average of $3.90 and a 200 day moving average of $3.94. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. Codexis, Inc. has a 12 month low of $2.43 and a 12 month high of $6.08. The firm has a market cap of $211.23 million, a P/E ratio of -2.93 and a beta of 2.12.

Codexis (NASDAQ:CDXS) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.09). The company had revenue of $21.46 million during the quarter, compared to the consensus estimate of $27.41 million. Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. As a group, research analysts forecast that Codexis, Inc. will post -0.77 EPS for the current year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.